Briefly describe the differences between capmatinib and lenvatinib

Capmatinib (Capmatinib) and lenvatinib are both targeted therapies, but they have significant differences in indications, mechanisms of action and clinical trial results.

First, capmatinib is designed to treat adult patients with non-small cell lung cancer (NSCLC) who have MET exon 14 skipping mutations. This drug provides patients with a personalized treatment strategy that targets this specific genetic alteration. In clinical trials, capmatinib demonstrated impressive efficacy, particularly in those untreated patients, with an overall response rate of 68%. Even for patients who have already received treatment, its overall efficacy rate reached 41%, which fully demonstrates its potential as a first-line or follow-up treatment for non-small cell lung cancer.

Relatively speaking, lenvatinib has a wider range of indications. It is approved for the treatment of differentiated thyroid cancer, in combination with renal cell carcinoma and endometrial cancer. Lenvatinib can inhibit the activity of multiple signaling pathways, includingVEGFR, FGFR, PDGFR, RET and KIT. In the pivotal Phase III clinical trial SELECT, lenvatinib significantly extended progression-free survival from 3.6 months to 18.3 months compared with placebo, bringing significant treatment improvements to patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

Although lenvatinib also showed some clinical activity in a phase II study in advanced medullary thyroid cancer (MTC), its effect was not as significant as in differentiated thyroid cancer. Therefore, its main field of application remains the treatment of RAI-R DTC.

In general, although capmatinib and lenvatinib are both oral tyrosine kinase inhibitors, their indications and mechanisms of action are significantly different. Patients must follow their doctor's advice and guidance when choosing to use these two drugs.